Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21/CDK4/6/Cyclin D1 axis driving tumorigenesis and drug resistance. https://www.biorxiv.org/content/10.1101/2022.11.09.515796
Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21/CDK4/6/Cyclin D1 axis driving tumorigenesis and drug resistance. https://www.biorxiv.org/content/10.1101/2022.11.09.515796